• 100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent therapy
  • Complete responses ("CRs") are rarely (0-8%) observed in metastatic pancreatic cancer in published studies evaluating chemotherapy-, checkpoint inhibitor-, and RAS inhibitor-based regimens
  • ELI-002 7P-induced mutant KRAS("mKRAS")-specific T cells may synergize with checkpoint inhibition to allow deep antitumor responses in a tumor type previously considered refractory to immunotherapy
  • Elicio believes these post-study observations build on mechanistic validation from prior AMPLIFY studies and support evaluation of ELI-002 7P in combination with checkpoint inhibition in metastatic pancreatic cancer
  • Elicio intends to initiate a Phase 1 study in metastatic pancreatic ductal adenocarcinoma ("PDAC") designed to provide a rapid assessment of clinical activity through a focused, confirmatory study, subject to funding
  • Elicio plans to use the study findings to further evaluate checkpoint inhibitor combinations and help inform future development strategies in metastatic PDAC and the adjuvant PDAC Phase 3 trial
  • Elicio is hosting a virtual key opinion leader event on Wednesday, June 24, 2026, at 1:00 PM ET, to further discuss these observations